Quick answers
- What is Pioglitazone and metformin hydrochloride used for?
- The FDA-approved label (Pioglitazone and metformin hydrochloride, Macleods Pharmaceuticals Limited, September 16, 2026) says: “Pioglitazone and metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus Limitations of Use Pioglitazone and metformin hydrochloride tablets is not recommended to treat type 1 diabetes mellitus or diabetic ketoacidosis. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the side effects of Pioglitazone and metformin hydrochloride?
- The “Adverse Reactions” section of the FDA label (Pioglitazone and metformin hydrochloride, Macleods Pharmaceuticals Limited, September 16, 2026) begins: “The following serious adverse reactions are discussed elsewhere in the labeling: • Congestive heart failure [see Boxed Warning, Warnings and Precautions (5.1)] • Lactic acidosis [see Boxed Warning, Warnings, and Precautions (5.2)] • Edema [see Warnings and Precautions (5.3)] • Fractures [see Warnings and Precautions (5.7)] • Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues [see Warnings and Precautions (5.4)] • Hepatic Effects [see Warnings and Precautions (5.5)] • Urinary Bladder Tumors [see Warnings and Precautions (5.6)] • Fractures [see Warnings and Precautions (5.7)] • Macular Edema [see Warnings and Precautions (5.8)] • Vitamin B 12 Deficiency [see Warnings and Precautions (5.9)] Most common adverse reactions (>5%) are upper respiratory tract infection, edema, diarrhea, headache and weight gain.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the drug interactions of Pioglitazone and metformin hydrochloride?
- The “Drug Interactions” section of the FDA label (Pioglitazone and metformin hydrochloride, Macleods Pharmaceuticals Limited, September 16, 2026) begins: “• Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.1) • CYP2C8 inducers (e.g., rifampin) may decrease pioglitazone concentrations. (7.2) • Carbonic anhydrase inhibitors may increase risk of lactic acidosis. Consider more frequent monitoring. (7.3) • Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Pioglitazone and metformin hydrochloride have a boxed warning?
- Yes. The FDA label for Pioglitazone and metformin hydrochloride has a boxed warning, the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
- Is there a shortage of Pioglitazone and metformin hydrochloride?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
- Has Pioglitazone and metformin hydrochloride been recalled?
- FDA enforcement reports list 1 recall of products of this medicine; the newest started January 24, 2020 (Class III). A recall usually concerns specific lots, not every product.
- Who makes Pioglitazone and metformin hydrochloride?
- 6 companies list prescription products of Pioglitazone and metformin hydrochloride in the FDA NDC Directory, including Bryant Ranch Prepack, Macleods Pharmaceuticals Limited and Aurobindo Pharma Limited.
What Pioglitazone and metformin hydrochloride is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Pioglitazone and metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus Limitations of Use Pioglitazone and metformin hydrochloride tablets is not recommended to treat type 1 diabetes mellitus or diabetic ketoacidosis. …
— FDA label: Pioglitazone and metformin hydrochloride, Macleods Pharmaceuticals Limited, effective September 16, 2026. Read the full label on DailyMed →
Label quoted: the one for the most common form (tablet, oral), Pioglitazone and metformin hydrochloride, Macleods Pharmaceuticals Limited; it covers 2 products in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.
The FDA has 9 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
This label has a boxed warning. Read it on the full label →
9 of 9 FDA labels for this medicine have a boxed warning.
Pioglitazone and metformin hydrochloride boxed warning: what the label says
Quoted from the boxed warning of the FDA-approved label.
WARNING: CONGESTIVE HEART FAILURE AND LACTIC ACIDOSIS FULL PRESCRIBING INFORMATION WARNING: CONGESTIVE HEART FAILURE and LACTIC ACIDOSIS Congestive Heart Failure
- Thiazolidinediones, including pioglitazone, which is a component of pioglitazone and metformin hydrochloride, cause or exacerbate congestive heart failure in some patients [see Warnings and Precautions (5.1)].
Read more of this section
- After initiation of pioglitazone and metformin hydrochloride, and after dose increases, monitor patients carefully for signs and symptoms of heart failure (e.g., excessive, rapid weight gain, dyspnea, and/or edema). If congestive heart failure develops while taking pioglitazone and metformin hydrochloride, consider discontinuation of pioglitazone and metformin hydrochloride or dosage reduction of pioglitazone in pioglitazone and metformin hydrochloride [see Warnings and Precautions (5.1)].
- Pioglitazone and metformin hydrochloride is not recommended in patients with symptomatic heart failure [see Warnings and Precautions (5.1)].
- Initiation of pioglitazone and metformin hydrochloride in patients with established New York Heart Association (NYHA) Class III or IV heart failure is contraindicated [see Contraindications (4), Warnings and Precautions (5.1)]. Lactic Acidosis
- Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmia's. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (greater than 5 mmol/L), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate:pyruvate ratio; and metformin plasma levels generally greater than 5 mcg/mL [see Warnings and Precautions (5.2)].
- Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic impairment, and mitochondrial diseases. [see warnings and precautions (5.2)]
- Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the Full Prescribing Information [see Dosage and Administration (2.2), Contraindications (4), Warnings and Precautions (5.2), Drug Interactions (7), Use in Specific Populations (8.6, 8.7)].
- If metformin-associated lactic acidosis is suspected, immediately discontinue pioglitazone and metformin hydrochloride tablets and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended [see Warnings and Precautions (5.2)].
— FDA label: Pioglitazone and metformin hydrochloride, Macleods Pharmaceuticals Limited, effective September 16, 2026. This is part of the section. Read the full label on DailyMed →
Pioglitazone and metformin hydrochloride side effects
Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.
The following serious adverse reactions are discussed elsewhere in the labeling:
- Congestive heart failure [see Boxed Warning, Warnings and Precautions (5.1)]
- Lactic acidosis [see Boxed Warning, Warnings, and Precautions (5.2)]
- Edema [see Warnings and Precautions (5.3)]
- Fractures [see Warnings and Precautions (5.7)]
- Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues [see Warnings and Precautions (5.4)]
- Hepatic Effects [see Warnings and Precautions (5.5)]
- Urinary Bladder Tumors [see Warnings and Precautions (5.6)]
- Fractures [see Warnings and Precautions (5.7)]
- Macular Edema [see Warnings and Precautions (5.8)]
- Vitamin B 12 Deficiency [see Warnings and Precautions (5.9)] Most common adverse reactions (>5%) are upper respiratory tract infection, edema, diarrhea, headache and weight gain.
Read more of this section
(6.1) To report SUSPECTED ADVERSE REACTIONS, contact Macleods Pharma USA, Inc. at 1-888-943-3210 or 1-855-926-3384 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Pioglitazone Over 8500 patients with type 2 diabetesmellitus have been treated with pioglitazone in randomized, double-blind, controlled clinical trials, including 2605 patients with type 2 diabetesmellitus and macrovascular disease treated with pioglitazone from the PROactive clinical trial. In these trials, over 6000 patients have been treated with pioglitazone for six months or longer, over 4500 patients have been treated with pioglitazone for one year or longer, and over 3000 patients have been treated with pioglitazone for at least two years. In six pooled 16- to 26-week placebo-controlled monotherapy and 16- to 24-week add-on combination therapy trials, the incidence of withdrawals due to adverse events was 4.5% for patients treated with pioglitazone and 5.8% for comparator-treated patients. The most common adverse events leading to withdrawal were related to inadequate glycemic control, although the incidence of these events was lower (1.5%) with pioglitazone than with placebo (3.0%). In the PROactive trial, the incidence of withdrawals due to adverse events was 9.0% for patients treated with pioglitazone and 7.7% for placebo-treated patients. Congestive heart failure was the most common serious adverse event leading to withdrawal occurring in 1.3% of patients treated with pioglitazone and 0.6% of patients treated with placebo. Common Adverse Events: 16- to 26-Week Monotherapy Trials A summary of the incidence and type of common adverse events reported in three pooled 16- to 26-week placebo-controlled monotherapy trials of pioglitazone is provided in Table 1. Terms that are reported represent those that occurred at an incidence of >5% and more commonly in patients treated with pioglitazone than in patients who received placebo. None of these adverse events were related to the pioglitazone dose. Table 2.
— FDA label: Pioglitazone and metformin hydrochloride, Macleods Pharmaceuticals Limited, effective September 16, 2026. This is part of the section. Read the full label on DailyMed →
Pioglitazone and metformin hydrochloride drug interactions
Quoted from the “Drug Interactions” section of the FDA-approved label. Tell your pharmacist about every medicine, vitamin and herbal product you take.
- Strong CYP2C8 inhibitors (e.g., gemfibrozil): Limit pioglitazone and metformin hydrochloride dose to 15 mg/850 mg daily. (7.1)
- CYP2C8 inducers (e.g., rifampin) may decrease pioglitazone concentrations. (7.2)
- Carbonic anhydrase inhibitors may increase risk of lactic acidosis. Consider more frequent monitoring. (7.3)
- Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin.
Read more of this section
Consider the benefits and risks of concomitant use. (7.4)
- Alcohol: Warn patients against excessive alcohol intake. (7.5)
- Use of insulin secretagogues or insulin use may increase the risk for hypoglycemia and may require dose reduction. (7.6)
- Topiramate may decrease pioglitazone concentrations. (7.8) 7.1 Strong CYP2C8 Inhibitors An inhibitor of CYP2C8 (e.g., gemfibrozil) significantly increases the exposure (area under the serum concentration-time curve or AUC) and half-life (t 1/2) of pioglitazone. Therefore, the maximum recommended dosage of pioglitazone and metformin hydrochloride tablets is 15 mg of pioglitazone and 850 mg of metformin HCl once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors [see Dosage and Administration (2.3), Clinical Pharmacology (12.3)]. 7.2 CYP2C8 Inducers An inducer of CYP2C8 (e.g., rifampin) may significantly decrease the exposure (AUC) of pioglitazone. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with pioglitazone and metformin hydrochloride tablets, changes in diabetes treatment may be needed based on clinical response without exceeding the maximum recommended daily dosage of pioglitazone and metformin hydrochloride tablets, (45 mg of pioglitazone and 2,550 mg of metformin HCl) [see Clinical Pharmacology (12.3)]. 7.3 Carbonic Anhydrase Inhibitors Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) frequently causes a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with pioglitazone and metformin hydrochloride tablets may increase the risk for lactic acidosis. Consider more frequent monitoring of these patients. 7.4 Drugs That Reduce Metformin Clearance Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2]/multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see Clinical Pharmacology (12.3)]. Consider the benefits and risks of concomitant use. 7.5 Alcohol Alcohol is known to potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake while receiving pioglitazone and metformin hydrochloride tablets. 7.6 Insulin Secretagogues or Insulin Coadministration of pioglitazone and metformin hydrochloride tablets with an insulin secretagogue (e.g., sulfonylurea) or insulin may increase the risk of hypoglycemia.
— FDA label: Pioglitazone and metformin hydrochloride, Macleods Pharmaceuticals Limited, effective September 16, 2026. This is part of the section. Read the full label on DailyMed →
Pioglitazone and metformin hydrochloride dosage
Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.
- Obtain liver tests before initiation. If abnormal, use caution when treating with pioglitazone and metformin hydrochloride, investigate the probable cause, treat (if possible), and follow appropriately. (2.1)
- Take orally with meals to reduce gastrointestinal adverse reactions with metformin (2.1)
- Individualize the starting dose based on the patient’s current regimen and titrate the dosage gradually, as needed after assessing therapeutic response and tolerability.
Read more of this section
The maximum recommended total daily dosage is pioglitazone 45 mg and metformin 2,550 mg. (2.2)
- Recommended starting dosage in patients with NYHA Class I or Class II congestive heart failure is 15 mg of pioglitazone and 850 mg of metformin HCl orally once daily. (2.4)
- Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR). (2.2) o Contraindicated in patients with eGFR below 30 mL/min o Initiation is not recommended in patients with eGFR between 30 to 45 mL/min o Assess risk/benefit of continuing pioglitazone and metformin hydrochloride if eGFR falls below 45 mL/min o Discontinue if eGFR falls below 30 mL/min
- Monitor patients for adverse events related to fluid retention after initiation and dose increases. (2.4)
- Pioglitazone and metformin hydrochloride may need to be discontinued at time of, or prior to, iodinated contrast imaging procedures. (2.6) 2.1 Important Dosage and Administration Information
- Obtain liver tests (serum alanine and aspartate aminotransferases, alkaline phosphatase, and total bilirubin) prior to initiating pioglitazone and metformin hydrochloride tablets [see Warnings and Precautions (5.5)].
- Pioglitazone and metformin hydrochloride tablets contain 15 mg of pioglitazone and 850 mg of metformin hydrochloride (HCl) in each tablet.
- Take pioglitazone and metformin hydrochloride tablets with meals to reduce gastrointestinal adverse reactions with metformin [see Adverse Reactions (6.1)].
- If a dose is missed, do not double the next dose 2.2 Recommended Dosage and Administration Recommended Starting Dosage Based on Current Regimen Individualize the starting dosage of pioglitazone and metformin hydrochloride tablets based on the patient's current regimen and the available strength of pioglitazone and metformin hydrochloride tablets (see Table 1). Table 1: Recommended Starting Dosage Based on the Patient’s Current Regimen Current Regimen Starting Dosage of pioglitazone and metformin Hydrochloride tablets (15 mg of pioglitazone and 850 mg of metformin HCl per tablet)* Not treated with either pioglitazone or metformin HCl One tablet orally once daily Metformin HCl One tablet orally once or twice daily.
Table from the label
| Current Regimen | Starting Dosage of pioglitazone and metformin Hydrochloride tablets (15 mg of pioglitazone and 850 mg of metformin HCl per tablet)* |
|---|---|
| Not treated with either pioglitazone or metformin HCl | One tablet orally once daily |
| Metformin HCl | One tablet orally once or twice daily. Select a dosage that is as close as possible to the current dosage of metformin HCl |
| Pioglitazone | One tablet orally once daily |
| Pioglitazone and metformin HCl | Select a dosage that is as close as possible to the current dosage of pioglitazone and metformin HCl while not exceeding three tablets orally per day. |
— FDA label: Pioglitazone and metformin hydrochloride, Macleods Pharmaceuticals Limited, effective September 16, 2026. This is part of the section. Read the full label on DailyMed →
Pioglitazone and metformin hydrochloride in pregnancy
Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.
Risk Summary Limited data with pioglitazone and metformin hydrochloride or pioglitazone in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. Published studies with metformin use during pregnancy have not reported a clear association with metformin and major birth defect or miscarriage risk [see Data].
Read more of this section
There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy [see Clinical Considerations]. In animal reproduction studies, no adverse developmental effects were observed when pioglitazone was administered to pregnant rats and rabbits during organogenesis at exposures up to 5- and 35-times the 45 mg clinical dose, respectively, based on body surface area. No adverse developmental effects were observed when metformin was administered to pregnant Sprague Dawley rats and rabbits during the period of organogenesis at doses up to 2- to 6-times, respectively, a 2000 mg clinical dose, based on body surface area [see Data]. The estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a HbA1c >7 and has been reported to be as high as 20-25% in women with a HbA1c >10. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, still birth and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, still birth, and macrosomia related morbidity. Data Human Data Published data from post-marketing studies have not reported a clear association with metformin and major birth defects, miscarriage, or adverse maternal or fetal outcomes when metformin was used during pregnancy. However, these studies cannot definitely establish the absence of any metformin-associated risk because of methodological limitations, including small sample size and inconsistent comparator groups. Animal Data Pioglitazone and Metformin HCl Animal reproduction studies were not conducted with the combined products in pioglitazone and metformin hydrochloride tablets. The following data are based on studies conducted with the individual components of pioglitazone and metformin hydrochloride tablets. Pioglitazone Pioglitazone administered to pregnant rats during organogenesis did not cause adverse developmental effects at a dose of 20 mg/kg (~5-times the 45 mg clinical dose), but delayed parturition and reduced embryofetal viability at 40 and 80 mg/kg, or ≥9-times the 45 mg clinical dose, by body surface area.
— FDA label: Pioglitazone and metformin hydrochloride, Macleods Pharmaceuticals Limited, effective September 16, 2026. This is part of the section. Read the full label on DailyMed →
Pioglitazone and metformin hydrochloride and breastfeeding
Quoted from the nursing mothers / lactation part of the FDA-approved label.
Females and Males of Reproductive Potential Discuss the potential for unintended pregnancy with premenopausal women as therapy with pioglitazone and metformin hydrochloride tablets, may result in ovulation in some anovulatory women.
— FDA label: Pioglitazone and metformin hydrochloride, Macleods Pharmaceuticals Limited, effective September 16, 2026. Read the full label on DailyMed →
When Pioglitazone and metformin hydrochloride should not be used
Quoted from the “Contraindications” section of the FDA-approved label.
Pioglitazone and metformin hydrochloride tablets are contraindicated in patients with:
- Established NYHA Class III or IV heart failure at the time of pioglitazone and metformin hydrochloride tablets initiation [see Boxed Warning].
- Severe renal impairment (eGFR below 30 mL/min) [see Warnings and Precautions (5.2)].
- A history of serious hypersensitivity to pioglitazone, metformin HCl, or any of the excipients in pioglitazone and metformin hydrochloride tablets.
Read more of this section
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis [see Warnings and Precautions (5.2)]. Pioglitazone and metformin hydrochloride tablets is contraindicated in patients with:
- Established NYHA Class III or IV heart failure at the time of pioglitazone and metformin hydrochloride tablets initiation [see Boxed Warning].
- Severe renal impairment (eGFR below 30 mL/min) [see Warnings and Precautions (5.2)].
- A history of serious hypersensitivity to pioglitazone, metformin HCl, or any of the excipients in pioglitazone and metformin hydrochloride tablets.
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis [see Warnings and Precautions (5.2)].
— FDA label: Pioglitazone and metformin hydrochloride, Macleods Pharmaceuticals Limited, effective September 16, 2026. Read the full label on DailyMed →
Pioglitazone and metformin hydrochloride overdose
Quoted from the “Overdosage” section of the FDA-approved label. If someone may have taken too much, call Poison Help at 1-800-222-1222 (or 911 in an emergency).
Pioglitazone During controlled clinical trials, one case of overdose with pioglitazone was reported. A male patient took 120 mg per day for four days, then 180 mg per day for seven days. The patient denied any clinical symptoms during this period. Metformin HCl Overdose of metformin HCl has occurred, including ingestion of amounts greater than 50 grams.
Read more of this section
Hypoglycemia was reported in approximately 10% of cases, but no causal association with metformin hydrochloride has been established. Lactic acidosis has been reported in approximately 32% of metformin overdose cases [see Warnings and Precautions (5.2)]. Metformin is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions. Therefore, hemodialysis may be useful for removal of accumulated metformin from patients in whom metformin overdosage is suspected. In the event of overdosage, contact the Poison Help Line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations. Appropriate supportive treatment should be initiated according to the patient’s clinical signs and symptoms.
— FDA label: Pioglitazone and metformin hydrochloride, Macleods Pharmaceuticals Limited, effective September 16, 2026. Read the full label on DailyMed →
Forms and how it is given
| Dosage forms | Tablet · Tablet, film coated |
|---|---|
| Route | Oral |
| Prescription products | 13 in the FDA NDC Directory |
| Brand names | Actoplus Met |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| metformin hydrochloride 500 mg · pioglitazone hydrochloride 15 mg tablet | Generic | $0.2940 per tablet |
| metformin hydrochloride 500 mg · pioglitazone hydrochloride 15 mg tablet, film coated | Generic | $0.2940 per tablet |
| metformin hydrochloride 850 mg · pioglitazone hydrochloride 15 mg tablet | Generic | $0.2083 per tablet |
| metformin hydrochloride 850 mg · pioglitazone hydrochloride 15 mg tablet, film coated | Generic | $0.2083 per tablet |
NADAC list of November 11, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Bryant Ranch Prepack4 products
- Macleods Pharmaceuticals Limited2 products
- Aurobindo Pharma Limited2 products
- Torrent Pharmaceuticals Limited2 products
- Rising Pharma Holdings, Inc.2 products
- Takeda Pharmaceuticals America, Inc.1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA021842 ACTOPLUS MET | Takeda Pharms USA | August 29, 2005 | 20, latest August 11, 2026 2026: Labeling · 2024: Labeling · 2017: Labeling |
Generic approvals (3)
- ANDA200823Aurobindo Pharma Ltd · February 13, 2013
- ANDA202001Torrent Pharms Ltd · February 13, 2013
- ANDA204802Macleods Pharms · November 5, 2015
Shortage status
The FDA drug shortage list does not show these products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
January 24, 2020 · Class III · Terminated · D-0838-2020
Subpotent Drug: Out of specification assay result, below specification, for two lots of Pioglitazone And Metformin Hydrochloride Tablets.
Pioglitazone and Metformin Hydrochloride Tablets, USP 15 mg/500 mg, Rx Only, 60-count bottle, Manufactured for Macleods Pharma USA, Inc. Plainsboro, NJ 08536, Manufactured by: Macleods Pharmaceuticals Ltd. Baddi, Himacha — Macleods Pharma Usa Inc
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
| RxCUI (RxNorm) | 861783, 861822, 861824 |
|---|---|
| SPL set ID of the quoted label | 5ff2cd9e-a579-48f5-845f-c37a68372a34 |
| FDA labels (SPL) | 9 |
| FDA applications | NDA021842, 3 ANDA |
| Active ingredients (FDA) | METFORMIN / PIOGLITAZONE |
Next steps
- Find a pharmacy near youAsk which price applies to you and whether your product is affected by a recall
- Latest FDA drug recallsAll medicines, newest first
- Actoplus MetBrand page: products, maker and price
- DiabetesCondition named on the label: hospitals that treat it
- Bryant Ranch PrepackMaker or distributor
- Macleods Pharmaceuticals LimitedMaker or distributor
- Aurobindo Pharma LimitedMaker or distributor
- All prescription drugs A to ZSearch by generic, brand or Spanish name
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Pioglitazone and metformin hydrochloride, Macleods Pharmaceuticals Limited, effective September 16, 2026; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →